BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, Gourgiotis D, Tsolia MN. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22. [PMID: 17712755 DOI: 10.1086/520983] [Cited by in Crossref: 158] [Cited by in F6Publishing: 165] [Article Influence: 9.9] [Reference Citation Analysis]
Number Citing Articles
1 Trajman A, Diallo T, Menzies D. Four months of rifampicin for tuberculosis prevention treatment in children. J Infect Chemother 2023;29:235. [PMID: 36371047 DOI: 10.1016/j.jiac.2022.10.016] [Reference Citation Analysis]
2 Chiang SS, Starke JR. Mycobacterium tuberculosis. Principles and Practice of Pediatric Infectious Diseases 2023. [DOI: 10.1016/b978-0-323-75608-2.00134-8] [Reference Citation Analysis]
3 Santos JM, Fachi MM, Beraldi-Magalhães F, Böger B, Junker AM, Domingos EL, Imazu P, Fernandez-Llimos F, Tonin FS, Pontarolo R. Systematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescents. J Infect Chemother 2022;28:1645-53. [PMID: 36075488 DOI: 10.1016/j.jiac.2022.08.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Abdollahi E, Keynan Y, Foucault P, Brophy J, Sheffield H, Moghadas SM. Evaluation of TB elimination strategies in Canadian Inuit populations: Nunavut as a case study. Infectious Disease Modelling 2022. [DOI: 10.1016/j.idm.2022.07.005] [Reference Citation Analysis]
5 Feiterna-sperling C. Tuberkulose bei Kindern und Jugendlichen unter Therapie mit TNF-α-Inhibitoren. Kinder- und Jugendmedizin 2022;22:223-230. [DOI: 10.1055/a-1854-1093] [Reference Citation Analysis]
6 Onyango DO, van der Sande MAB, Yuen CM, Mecha J, Matemo D, Oele E, Kinuthia J, John-Stewart G, LaCourse SM. Drop-offs in the isoniazid preventive therapy cascade among children living with HIV in western Kenya, 2015-2019. J Int AIDS Soc 2022;25:e25939. [PMID: 35927793 DOI: 10.1002/jia2.25939] [Reference Citation Analysis]
7 Feiterna-Sperling C, Thoulass J, Krüger R, Haas W, Hauer B. Pilot study to identify missed opportunities for prevention of childhood tuberculosis. Eur J Pediatr 2022. [PMID: 35771355 DOI: 10.1007/s00431-022-04537-1] [Reference Citation Analysis]
8 Khan DSA, Naseem R, Salam RA, Lassi ZS, Das JK, Bhutta ZA. Interventions for High-Burden Infectious Diseases in Children and Adolescents: A Meta-analysis. Pediatrics 2022;149. [DOI: 10.1542/peds.2021-053852c] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Jaganath D, Beaudry J, Salazar-austin N. Tuberculosis in Children. Infectious Disease Clinics of North America 2022;36:49-71. [DOI: 10.1016/j.idc.2021.11.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Migliori GB, Wu SJ, Matteelli A, Zenner D, Goletti D, Ahmedov S, Al-Abri S, Allen DM, Balcells ME, Garcia-Basteiro AL, Cambau E, Chaisson RE, Chee CBE, Dalcolmo MP, Denholm JT, Erkens C, Esposito S, Farnia P, Friedland JS, Graham S, Hamada Y, Harries AD, Kay AW, Kritski A, Manga S, Marais BJ, Menzies D, Ng D, Petrone L, Rendon A, Silva DR, Schaaf HS, Skrahina A, Sotgiu G, Thwaites G, Tiberi S, Tukvadze N, Zellweger JP, D Ambrosio L, Centis R, Ong CWM. Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis 2022;26:190-205. [PMID: 35197159 DOI: 10.5588/ijtld.21.0753] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
11 Mckenna L, Sari AH, Mane S, Scardigli A, Brigden G, Rouzier V, Becerra MC, Hesseling AC, Amanullah F. Pediatric Tuberculosis Research and Development: Progress, Priorities and Funding Opportunities. Pathogens 2022;11:128. [DOI: 10.3390/pathogens11020128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Lu W, Zhu L, Liu Q, Chen C, Lu P, Ding X, Shao Y, Li Y. Progress in Epidemiology of Tuberculosis in China. Progress in China Epidemiology 2022. [DOI: 10.1007/978-981-19-2199-5_8] [Reference Citation Analysis]
13 Diel R, Magdorf K. Lungentuberkulose und andere Mykobakteriosen. Therapie-Handbuch - Pneumologie 2022. [DOI: 10.1016/b978-3-437-23814-7.00005-x] [Reference Citation Analysis]
14 Singh M, Kaur K, Chauhan A, Singh M, Sra H, Pradhan P, Rana M, Saini S, Shafiq N. Isoniazid versus alternative regimens for the treatment of latent tuberculosis in children: A systematic review and network meta-analysis. J Pediatr Pulmonol 2022;1:55. [DOI: 10.4103/jopp.jopp_21_22] [Reference Citation Analysis]
15 González-martínez A, Olivares-duran M, Gutiérrez-bautista JF, Reguera Márquez J, Aliaga L, Rodríguez-granger J. Mycobacterium infections. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00216-0] [Reference Citation Analysis]
16 Vasiliu A, Salazar-Austin N, Trajman A, Lestari T, Mtetwa G, Bonnet M, Casenghi M. Child Contact Case Management-A Major Policy-Practice Gap in High-Burden Countries. Pathogens 2021;11:1. [PMID: 35055949 DOI: 10.3390/pathogens11010001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Heffernan C, Rowe BH, Long R. Engaging frontline providers: an important key to eliminating tuberculosis in Canada, and other high-income countries. Can J Public Health 2021;112:872-6. [PMID: 34515944 DOI: 10.17269/s41997-021-00556-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yoo H, Chun Ji S, Cho JY, Kim SH, Yoon JG, Goo Lee M, Yu KS, Jang IJ, Oh J. A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators. Pharmacogenet Genomics 2021;31:68-73. [PMID: 33165168 DOI: 10.1097/FPC.0000000000000423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
19 Chatzitaki AT, Mystiridou E, Bouropoulos N, Ritzoulis C, Karavasili C, Fatouros DG. Semi-solid extrusion 3D printing of starch-based soft dosage forms for the treatment of paediatric latent tuberculosis infection. J Pharm Pharmacol 2021:rgab121. [PMID: 34468746 DOI: 10.1093/jpp/rgab121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Campbell JI, Sandora TJ, Haberer JE. A scoping review of paediatric latent tuberculosis infection care cascades: initial steps are lacking. BMJ Glob Health 2021;6:e004836. [PMID: 34016576 DOI: 10.1136/bmjgh-2020-004836] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
21 von Both U, Gerlach P, Ritz N, Bogyi M, Brinkmann F, Thee S. Management of childhood and adolescent latent tuberculous infection (LTBI) in Germany, Austria and Switzerland. PLoS One 2021;16:e0250387. [PMID: 33970930 DOI: 10.1371/journal.pone.0250387] [Reference Citation Analysis]
22 Starke JR. Tuberculosis in Infants and Children. Tuberculosis and Nontuberculous Mycobacterial Infections 2021. [DOI: 10.1128/9781555817138.ch30] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Subramanian AK. Mycobacterium tuberculosis in Transplantation. Emerging Transplant Infections 2021. [DOI: 10.1007/978-3-030-25869-6_15] [Reference Citation Analysis]
24 Kay AW, Thivalapill N, Skinner D, Dube GS, Dlamini N, Mzileni B, Fuentes P, Ustero P, Adams LV, Mandalakas AM. Predictors of suboptimal adherence to isoniazid preventive therapy among adolescents and children living with HIV. PLoS One 2020;15:e0243713. [PMID: 33332462 DOI: 10.1371/journal.pone.0243713] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
25 Rajpal S, Arora VK. Latent TB (LTBI) treatment: Challenges in India with an eye on 2025: "To Treat LTBI or not to treat, that is the question". Indian J Tuberc 2020;67:S43-7. [PMID: 33308671 DOI: 10.1016/j.ijtb.2020.09.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Stewart RJ, Wortham J, Parvez F, Morris SB, Kirking HL, Cameron LH, Cruz AT. Tuberculosis Infection in Children. The Journal for Nurse Practitioners 2020;16:673-8. [DOI: 10.1016/j.nurpra.2020.06.027] [Reference Citation Analysis]
27 Dorjee K, Topgyal S, Dorjee C, Tsundue T, Namdol T, Tsewang T, Nangsel T, Lhadon D, Choetso T, Dawa T, Phentok T, DeLuca AN, Tsering L, Phunkyi D, Sadutshang TD, J Bonomo E, Paster Z, Chaisson RE. High Prevalence of Active and Latent Tuberculosis in Children and Adolescents in Tibetan Schools in India: The Zero TB Kids Initiative in Tibetan Refugee Children. Clin Infect Dis 2019;69:760-8. [PMID: 30462191 DOI: 10.1093/cid/ciy987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
28 Adepoju AV, Ogbudebe CL, Adejumo OA, Okolie J, Inegbeboh JO. Implementation of Isoniazid Preventive Therapy among People Living with HIV in Northwestern Nigeria: Completion Rate and Predictive Factors. J Glob Infect Dis 2020;12:105-11. [PMID: 32773999 DOI: 10.4103/jgid.jgid_138_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Cole B, Nilsen DM, Will L, Etkind SC, Burgos M, Chorba T. Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers Association. MMWR Recomm Rep 2020;69:1-27. [PMID: 32730235 DOI: 10.15585/mmwr.rr6907a1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
30 Bares SH, Swindells S. Latent Tuberculosis and HIV Infection. Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00726-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. Am J Respir Crit Care Med 2020;201:598-605. [PMID: 31711306 DOI: 10.1164/rccm.201908-1606OC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
32 Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clin Chest Med 2019;40:839-48. [PMID: 31731988 DOI: 10.1016/j.ccm.2019.07.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
33 Money NM, Schroeder AR, Quinonez RA, Ho T, Marin JR, Morgan DJ, Dhruva SS, Coon ER. 2019 Update on Pediatric Medical Overuse: A Systematic Review. JAMA Pediatr 2020;174:375. [DOI: 10.1001/jamapediatrics.2019.5849] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
34 Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR, Crane CM, Burgos M, Lobue P, Winston CA, Belknap R. Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. Am J Transplant 2020;20:1196-206. [DOI: 10.1111/ajt.15841] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
35 Fröberg G, Jansson L, Nyberg K, Obasi B, Westling K, Berggren I, Bruchfeld J. Screening and treatment of tuberculosis among pregnant women in Stockholm, Sweden, 2016-2017. Eur Respir J 2020;55:1900851. [PMID: 31949114 DOI: 10.1183/13993003.00851-2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Reuter A, Seddon JA, Marais BJ, Furin J. Preventing tuberculosis in children: A global health emergency. Paediatr Respir Rev 2020;36:44-51. [PMID: 32253128 DOI: 10.1016/j.prrv.2020.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
37 Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020;69:1-11. [PMID: 32053584 DOI: 10.15585/mmwr.rr6901a1] [Cited by in Crossref: 117] [Cited by in F6Publishing: 130] [Article Influence: 39.0] [Reference Citation Analysis]
38 Subramanian AK. Mycobacterium tuberculosis in Transplantation. Emerging Transplant Infections 2020. [DOI: 10.1007/978-3-030-01751-4_15-1] [Reference Citation Analysis]
39 Otero L, Battaglioli T, Ríos J, De la Torre Z, Trocones N, Ordoñez C, Seas C, Van der Stuyft P. Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data. Trop Med Int Health 2020;25:346-56. [PMID: 31758837 DOI: 10.1111/tmi.13350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
40 Lange C, Kalsdorf B, Maurer FP, Heyckendorf J. Tuberkulose. Internist 2019;60:1155-75. [DOI: 10.1007/s00108-019-00685-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
41 Panagiotopoulos T. Screening for infectious diseases in newly arrived migrants in Europe: the context matters. Euro Surveill 2018;23. [PMID: 30017023 DOI: 10.2807/1560-7917.ES.2018.23.28.1800283] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
42 Doddam SN, Peddireddy V, Yerra P, Sai Arun PP, Qaria MA, Baddam R, Sarker N, Ahmed N. Mycobacterium tuberculosis DosR regulon gene Rv2004c contributes to streptomycin resistance and intracellular survival. Int J Med Microbiol 2019;309:151353. [PMID: 31521502 DOI: 10.1016/j.ijmm.2019.151353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
43 Santos JC, Silva JB, Rangel MA, Barbosa L, Carvalho I. Preventive therapy compliance in pediatric tuberculosis - A single center experience. Pulmonology 2020;26:78-83. [PMID: 31427215 DOI: 10.1016/j.pulmoe.2019.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
44 Paton NI, Borand L, Benedicto J, Kyi MM, Mahmud AM, Norazmi MN, Sharma N, Chuchottaworn C, Huang YW, Kaswandani N, Le Van H, Lui GCY, Mao TE. Diagnosis and management of latent tuberculosis infection in Asia: Review of current status and challenges. Int J Infect Dis 2019;87:21-9. [PMID: 31301458 DOI: 10.1016/j.ijid.2019.07.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
45 Unterweger M, Götzinger F, Bogyi M, Zacharasiewicz A, Mädel C, Tiringer K, Reinweber M, Frischer T. Childhood tuberculosis in Vienna between 2010 and 2016. Wien Klin Wochenschr 2019;131:356-61. [PMID: 31123816 DOI: 10.1007/s00508-019-1510-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Venturini E, Tersigni C, Cordola C, de Martino M, Galli L. Latent Tuberculosis Treatment Compliance in Children: A 10-Year Experience. Pediatr Infect Dis J 2018;37:617. [PMID: 29762390 DOI: 10.1097/INF.0000000000001857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Subramanian AK, Theodoropoulos NM; Infectious Diseases Community of Practice of the American Society of Transplantation. Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transplant 2019;33:e13513. [PMID: 30817030 DOI: 10.1111/ctr.13513] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 12.3] [Reference Citation Analysis]
48 Jain A, Lodha R. Management of Latent Tuberculosis Infection in Children from Developing Countries. Indian J Pediatr 2019;86:740-5. [PMID: 30741387 DOI: 10.1007/s12098-019-02861-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
49 Marais BJ. Newer Drugs for Tuberculosis Prevention and Treatment in Children. Indian J Pediatr 2019;86:725-31. [PMID: 30707347 DOI: 10.1007/s12098-018-02854-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
50 Garessus EDG, Mielke H, Gundert-Remy U. Exposure of Infants to Isoniazid via Breast Milk After Maternal Drug Intake of Recommended Doses Is Clinically Insignificant Irrespective of Metaboliser Status. A Physiologically-Based Pharmacokinetic (PBPK) Modelling Approach to Estimate Drug Exposure of Infants via Breast-Feeding. Front Pharmacol 2019;10:5. [PMID: 30723406 DOI: 10.3389/fphar.2019.00005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
51 Gaensbauer J, Aiona K, Haas M, Reves R, Young J, Belknap R. Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic. Pediatr Infect Dis J 2018;37:224-8. [PMID: 28777204 DOI: 10.1097/INF.0000000000001721] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
52 Mwangi PM, Wamalwa D, Marangu D, Obimbo EM, Ng'ang'a M. Implementation of Isoniazid Preventive Therapy Among HIV-Infected Children at Health Facilities in Nairobi County, Kenya: A Cross-Sectional Study. East Afr Health Res J 2019;3:141-50. [PMID: 34308207 DOI: 10.24248/EAHRJ-D-19-00005] [Reference Citation Analysis]
53 Hwang WJ, Lee GU, Kim SH, Cho EY. Childhood Tuberculosis Contact Investigation and Treatment of Latent Tuberculosis Infection: a Single Center Study, 2014–2017. Pediatr Infect Vaccine 2019;26:32. [DOI: 10.14776/piv.2019.26.e4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
54 Diel R, Loddenkemper R, Magdorf K. Lungentuberkulose und andere Mykobakteriosen. Therapie-Handbuch 2019. [DOI: 10.1016/b978-3-437-24951-8.00014-2] [Reference Citation Analysis]
55 Epstein DJ, Subramanian AK. Prevention and Management of Tuberculosis in Solid Organ Transplant Recipients. Infect Dis Clin North Am. 2018;32:703-718. [PMID: 30146031 DOI: 10.1016/j.idc.2018.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
56 Lee SH. Diagnosis and Treatment of Latent Tuberculosis Infection: The Updated 2017 Korean Guidelines. Korean J Med 2018;93:509-17. [DOI: 10.3904/kjm.2018.93.6.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
57 Rendon A, Goletti D, Matteelli A. Diagnosis and treatment of latent tuberculosis infection. Tuberculosis. [DOI: 10.1183/2312508x.10022617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
58 Knezevic DA, Jampol LM, Gupta A. Diagnostic and Therapeutic Challenges. Retina 2018;38:2096-2102. [DOI: 10.1097/iae.0000000000002287] [Reference Citation Analysis]
59 Hatzenbuehler LA, Starke JR. Treatment of tuberculosis infection in children. Expert Rev Anti Infect Ther 2018;16:695-708. [PMID: 30132364 DOI: 10.1080/14787210.2018.1513324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Assefa Y, Assefa Y, Woldeyohannes S, Hamada Y, Getahun H. 3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review. Eur Respir J 2018;52:1800395. [PMID: 29748305 DOI: 10.1183/13993003.00395-2018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
61 Sun HY, Huang YW, Huang WC, Chang LY, Chan PC, Chuang YC, Ruan SY, Wang JY, Wang JT. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb) 2018;111:121-6. [PMID: 30029896 DOI: 10.1016/j.tube.2018.05.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
62 McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, Msandiwa R, Wiesner L, Velaphi S, Lala SG, Chaisson RE, Martinson N, Dooley KE; Tshepiso Study Team. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. J Antimicrob Chemother 2017;72:2028-34. [PMID: 28419277 DOI: 10.1093/jac/dkx112] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
63 Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, Skidmore B, Alvarez GG. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf 2018;27:557-66. [DOI: 10.1002/pds.4423] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
64 Mueller-Hermelink M, Kobbe R, Methling B, Rau C, Schulze-Sturm U, Auer I, Ahrens F, Brinkmann F. Universal screening for latent and active tuberculosis (TB) in asylum seeking children, Bochum and Hamburg, Germany, September 2015 to November 2016. Euro Surveill 2018;23. [PMID: 29589578 DOI: 10.2807/1560-7917.ES.2018.23.12.17-00536] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
65 Sekadde MP, Kay AW. Tuberculosis Prevention: an Under Prioritized yet Critical Intervention to Reduce Child Tuberculosis Morbidity and Mortality. Curr Trop Med Rep 2018;5:51-8. [DOI: 10.1007/s40475-018-0139-5] [Reference Citation Analysis]
66 Tersigni C, Venturini E, Cordola C, Piccini P, Bianchi L, Montagnani C, Sollai S, Chiappini E, de Martino M, Galli L. Latent tuberculosis in childhood: tolerability of two different therapeutic approaches. Expert Rev Anti Infect Ther 2018;16:359-65. [PMID: 29465259 DOI: 10.1080/14787210.2018.1441025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Chiang SS, Starke JR. Mycobacterium tuberculosis. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 790-806.e5. [DOI: 10.1016/b978-0-323-40181-4.00134-1] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
68 Lee EH, Kang YA, Leem AY, Park MS, Kim YS, Kim SK, Chang J, Kim SY. Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection. Sci Rep 2017;7:6473. [PMID: 28743918 DOI: 10.1038/s41598-017-06899-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
69 Lamb GS, Starke JR. Tuberculosis in Infants and Children. Microbiol Spectr 2017;5. [PMID: 28387193 DOI: 10.1128/microbiolspec.TNMI7-0037-2016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
70 Haley CA. Treatment of Latent Tuberculosis Infection. Tuberculosis and Nontuberculous Mycobacterial Infections 2017. [DOI: 10.1128/9781555819866.ch6] [Reference Citation Analysis]
71 Lamb GS, Starke JR. Tuberculosis in Infants and children. Tuberculosis and Nontuberculous Mycobacterial Infections 2017. [DOI: 10.1128/9781555819866.ch32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Haley CA. Treatment of Latent Tuberculosis Infection. Microbiol Spectr 2017;5. [PMID: 28409555 DOI: 10.1128/microbiolspec.TNMI7-0039-2016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
73 Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, Skidmore B, Moher D, Alvarez GG. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis 2017;17:265. [PMID: 28399802 DOI: 10.1186/s12879-017-2377-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 7.7] [Reference Citation Analysis]
74 Venturini E, Tersigni C, Chiappini E, de Martino M, Galli L. Optimizing the management of children with latent tuberculosis infection. Expert Rev Anti Infect Ther 2017;15:341-9. [PMID: 28074660 DOI: 10.1080/14787210.2017.1279541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
75 Xiao H, Tang S, Sha W, Zhang Q, Zhao J. Drug-Resistant TB. Handbook of Global Tuberculosis Control 2017. [DOI: 10.1007/978-1-4939-6667-7_10] [Reference Citation Analysis]
76 Salazar-austin N, Jain S, Dooley KE. Management of Tuberculosis in Special Populations. Handbook of Tuberculosis 2017. [DOI: 10.1007/978-3-319-26273-4_6] [Reference Citation Analysis]
77 Fox GJ, Dobler CC, Marais BJ, Denholm JT. Preventive therapy for latent tuberculosis infection-the promise and the challenges. Int J Infect Dis 2017;56:68-76. [PMID: 27872018 DOI: 10.1016/j.ijid.2016.11.006] [Cited by in Crossref: 83] [Cited by in F6Publishing: 90] [Article Influence: 11.9] [Reference Citation Analysis]
78 Mathivha KT, Velaphi S. Characteristics of infants exposed to maternal tuberculosis and chemoprophylaxis using 3 months of isoniazid and rifampicin. Paediatr Int Child Health 2017;37:129-34. [PMID: 27455907 DOI: 10.1080/20469047.2016.1200288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
79 Stuurman AL, Vonk Noordegraaf-Schouten M, van Kessel F, Oordt-Speets AM, Sandgren A, van der Werf MJ. Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC Infect Dis 2016;16:257. [PMID: 27268103 DOI: 10.1186/s12879-016-1549-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]
80 Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van der Werf MJ. Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis 2016;16:204. [PMID: 27184748 DOI: 10.1186/s12879-016-1550-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
81 Brinkmann F. Zeitnahe Untersuchung ist von großer Wichtigkeit. Pädiatrie 2016;28:24-29. [DOI: 10.1007/s15014-016-0658-2] [Reference Citation Analysis]
82 Haukaas FS, Arnesen TM, Winje BA, Aas E. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis. Eur J Health Econ 2017;18:405-15. [DOI: 10.1007/s10198-016-0779-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
83 Isoniazid. Meyler's Side Effects of Drugs 2016. [DOI: 10.1016/b978-0-444-53717-1.00925-2] [Reference Citation Analysis]
84 Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015;46:1563-76. [PMID: 26405286 DOI: 10.1183/13993003.01245-2015] [Cited by in Crossref: 353] [Cited by in F6Publishing: 375] [Article Influence: 44.1] [Reference Citation Analysis]
85 Catho G, Sénéchal A, Ronnaux-Baron AS, Valour F, Perpoint T, Bouaziz A, Dumitriescu O, Reix P, Pedone C, Ader F; Lyon TB Study Group. [Children exposed to multidrug-resistant tuberculosis: How should we manage? Analysis of 46 child contacts and review of the literature]. Rev Pneumol Clin 2015;71:335-41. [PMID: 26195117 DOI: 10.1016/j.pneumo.2015.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
86 Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Evid Based Child Health. 2014;9:169-294. [PMID: 25404581 DOI: 10.1002/ebch.1962] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
87 Leeb S, Buxbaum C, Fischler B. Elevated transaminases are common in children on prophylactic treatment for tuberculosis. Acta Paediatr 2015;104:479-84. [PMID: 25619878 DOI: 10.1111/apa.12908] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
88 Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group., Tuberculosis Trials Consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr 2015;169:247-55. [PMID: 25580725 DOI: 10.1001/jamapediatrics.2014.3158] [Cited by in Crossref: 133] [Cited by in F6Publishing: 145] [Article Influence: 16.6] [Reference Citation Analysis]
89 Lee SH. Diagnosis and treatment of latent tuberculosis infection. Tuberc Respir Dis (Seoul) 2015;78:56-63. [PMID: 25861337 DOI: 10.4046/trd.2015.78.2.56] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
90 Bamford A, Turkova A, Lyall H, Foster C, Klein N, Bastiaans D, Burger D, Bernadi S, Butler K, Chiappini E, Clayden P, Della Negra M, Giacomet V, Giaquinto C, Gibb D, Galli L, Hainaut M, Koros M, Marques L, Nastouli E, Niehues T, Noguera-Julian A, Rojo P, Rudin C, Scherpbier HJ, Tudor-Williams G, Welch SB; (PENTA Steering Committee). Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. HIV Med 2018;19:e1-e42. [PMID: 25649230 DOI: 10.1111/hiv.12217] [Cited by in Crossref: 56] [Cited by in F6Publishing: 69] [Article Influence: 7.0] [Reference Citation Analysis]
91 Clifford V, Zufferey C, Street A, Denholm J, Tebruegge M, Curtis N. Cytokines for monitoring anti-tuberculous therapy: A systematic review. Tuberculosis (Edinb) 2015;95:217-28. [PMID: 25797612 DOI: 10.1016/j.tube.2015.01.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
92 Loddenkemper R, Siemon G, Castell S, Magdorf K. Lungentuberkulose und andere Mykobakteriosen. Therapie-Handbuch Grundwerk inkl 6. Lfg. 2015. [DOI: 10.1016/b978-3-437-22107-1.50105-9] [Reference Citation Analysis]
93 Drug monographs. Neonatal Formulary 7 2014. [DOI: 10.1002/9781118819494.ch15] [Reference Citation Analysis]
94 Marais BJ, Schaaf HS. Tuberculosis in children. Cold Spring Harb Perspect Med 2014;4:a017855. [PMID: 25037105 DOI: 10.1101/cshperspect.a017855] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
95 Hatzenbuehler LA, Starke JR. Current Diagnosis and Treatment of Pediatric Latent Tuberculosis Infection. Curr Pediatr Rep 2014;2:145-55. [DOI: 10.1007/s40124-014-0054-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
96 Hamzaoui A. [Childhood tuberculosis]. Rev Pneumol Clin 2015;71:168-80. [PMID: 24932504 DOI: 10.1016/j.pneumo.2014.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
97 Anibarro L, Pena A. Tuberculosis in patients with haematological malignancies. Mediterr J Hematol Infect Dis 2014;6:e2014026. [PMID: 24803999 DOI: 10.4084/MJHID.2014.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
98 Marcos Sánchez F, Blanco Jarava A, Yzusqui Mendoza M, Vizuete Calero A, Magallanes Gamboa J. Tuberculosis. Medicine - Programa de Formación Médica Continuada Acreditado 2014;11:3054-3062. [DOI: 10.1016/s0304-5412(14)70739-5] [Reference Citation Analysis]
99 Brinkmann F, Thee S, Ritz N. Tuberkulose im Kindesalter. Pneumologe 2014;11:161-170. [DOI: 10.1007/s10405-014-0779-7] [Reference Citation Analysis]
100 Marais BJ. Tuberculosis in children. J Paediatr Child Health 2014;50:759-67. [PMID: 24548085 DOI: 10.1111/jpc.12503] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
101 Brinkmann F, Thee S. Update zur Therapie der Tuberkulose im Kindesalter. Monatsschr Kinderheilkd 2014;162:122-129. [DOI: 10.1007/s00112-013-2964-x] [Reference Citation Analysis]
102 Indumathi C, Kumar G, Sethuraman A, Iyengar A. Evaluation of efficacy and adherence to INH preventive therapy in children at risk to develop active tuberculosis. Pediatric Infectious Disease 2014;6:21-24. [DOI: 10.1016/j.pid.2014.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
103 Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;:CD007545. [PMID: 23828580 DOI: 10.1002/14651858.CD007545.pub2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
104 Gwee A, Coghlan B, Curtis N. Question 1: what are the options for treating latent TB infection in children? Arch Dis Child 2013;98:468-74. [PMID: 23661667 DOI: 10.1136/archdischild-2013-303876] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
105 Cruz AT, Ahmed A, Mandalakas AM, Starke JR. Treatment of Latent Tuberculosis Infection in Children. J Pediatric Infect Dis Soc 2013;2:248-58. [PMID: 26619479 DOI: 10.1093/jpids/pit030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
106 Chen SC, Chen KL, Chen KH, Chien ST, Chen KT. Updated diagnosis and treatment of childhood tuberculosis. World J Pediatr 2013;9:9-16. [PMID: 23389330 DOI: 10.1007/s12519-013-0404-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
107 Chee CB, Sester M, Zhang W, Lange C. Diagnosis and treatment of latent infection with Mycobacterium tuberculosis: LTBI diagnosis and treatment. Respirology 2013;18:205-16. [DOI: 10.1111/resp.12002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
108 Cruz AT, Mandalakas AM. New advances in the diagnosis and treatment of pediatric tuberculosis. Clinical Investigation 2013;3:69-82. [DOI: 10.4155/cli.12.139] [Reference Citation Analysis]
109 Atmungsorgane. Therapie–Handbuch Infektiologie 2013. [DOI: 10.1016/b978-3-437-22073-9.00005-x] [Reference Citation Analysis]
110 Rutherford ME, Hill PC, Triasih R, Sinfield R, van Crevel R, Graham SM. Preventive therapy in children exposed to Mycobacterium tuberculosis: problems and solutions. Trop Med Int Health 2012;17:1264-73. [PMID: 22862994 DOI: 10.1111/j.1365-3156.2012.03053.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
111 Magira EE, Papasteriades C, Kanterakis S, Toubis M, Roussos C, Monos DS. HLA-A and HLA-DRB1 amino acid polymorphisms are associated with susceptibility and protection to pulmonary tuberculosis in a Greek population. Human Immunology 2012;73:641-6. [DOI: 10.1016/j.humimm.2012.03.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
112 Fraisse P. Traitement des infections tuberculeuses latentes. Revue des Maladies Respiratoires 2012;29:579-600. [DOI: 10.1016/j.rmr.2011.07.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
113 Larppanichpoonphol P, Bagdure S, Amiri HM, Nugent K. Poor Compliance Makes Treatment of Latent Tuberculosis Infection Unsatisfactory. J Prim Care Community Health 2012;3:246-50. [DOI: 10.1177/2150131912437936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
114 Kaneko T, Cooper C, Mdluli K. Challenges and opportunities in developing novel drugs for TB. Future Med Chem 2011;3:1373-400. [PMID: 21879843 DOI: 10.4155/fmc.11.115] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
115 Starke JR. Mycobacterium tuberculosis. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2012. pp. 771-786.e6. [DOI: 10.1016/b978-1-4377-2702-9.00136-7] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
116 Marais BJ. What Do We Know About How to Treat Tuberculosis? Advances in Experimental Medicine and Biology 2012. [DOI: 10.1007/978-1-4614-0204-6_15] [Reference Citation Analysis]
117 Benjumea D. Tratamiento para la infección latente por tuberculosis en niños: recomendaciones internacionales y para Colombia. Infectio 2012;16:173-7. [DOI: 10.1016/s0123-9392(12)70008-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Shim TS. Diagnosis and Treatment of Latent Tuberculosis Infection. Korean J Med 2012;82:284. [DOI: 10.3904/kjm.2012.82.3.284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
119 Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3:e16. [PMID: 21772953 DOI: 10.4081/pr.2011.e16] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]
120 Fraisse P, Mohammad Y, Delacourt C, Roche A. Enfant exposé à un patient tuberculeux : agir vite. Revue des Maladies Respiratoires Actualités 2011;3:182-184. [DOI: 10.1016/s1877-1203(11)70087-8] [Reference Citation Analysis]
121 Clerk N, Sisson K, Antunes G. Latent tuberculosis: concordance and duration of treatment regimens. Br J Nurs 2011;20:824-7. [PMID: 21841691 DOI: 10.12968/bjon.2011.20.13.824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
122 Fraisse P. Le traitement antibiotique de l’infection tuberculeuse latente. Rationnel scientifique et régimes thérapeutiques. Journal des Anti-infectieux 2011;13:191-200. [DOI: 10.1016/j.antinf.2011.07.002] [Reference Citation Analysis]
123 Khan FY, Rasoul F. Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review. Indian J Crit Care Med 2010;14:97-100. [PMID: 20859496 DOI: 10.4103/0972-5229.68226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
124 Delacourt C. [Specific features of tuberculosis in childhood]. Rev Mal Respir 2011;28:529-41. [PMID: 21549907 DOI: 10.1016/j.rmr.2010.10.038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
125 . Part Introduction. Neonatal Formulary 6 2011. [DOI: 10.1002/9781444329773.part2] [Reference Citation Analysis]
126 Duarte R, Villar M, Carvalho A. [Latent tuberculosis infection treatment. Current recommendations]. Rev Port Pneumol 2010;16:809-14. [PMID: 20927496 DOI: 10.1016/s0873-2159(15)30073-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
127 Starke JR. Tuberculosis (Mycobacterium tuberculosis). Nelson Textbook of Pediatrics 2011. [DOI: 10.1016/b978-1-4377-0755-7.00207-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
128 Ahmad S. New approaches in the diagnosis and treatment of latent tuberculosis infection. Respir Res 2010;11:169. [PMID: 21126375 DOI: 10.1186/1465-9921-11-169] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
129 Singh M, Saini AG, Anil N, Aggarwal A. Latent Tuberculosis in Children: Diagnosis and Management. Indian J Pediatr 2011;78:464-8. [DOI: 10.1007/s12098-010-0295-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
130 Marais BJ, Schaaf HS. Childhood tuberculosis: an emerging and previously neglected problem. Infect Dis Clin North Am 2010;24:727-49. [PMID: 20674801 DOI: 10.1016/j.idc.2010.04.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
131 Singh V, Patra S. A Relook at Preventive Therapy for Tuberculosis in Children. Indian J Pediatr 2011;78:205-10. [DOI: 10.1007/s12098-010-0257-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
132 Duarte R, Villar M, Carvalho A. Tratamento da tuberculose de infecção latente. As recomendações actuais. Revista Portuguesa de Pneumologia (English Edition) 2010;16:809-814. [DOI: 10.1016/s2173-5115(10)70079-8] [Reference Citation Analysis]
133 Salinas C, Pascual Erquicia S, Diez R, Aguirre U, Egurrola M, Altube L, Capelastegui A. Pauta de tres meses de rifampicina e isoniacida para el tratamiento de la infección latente tuberculosa. Medicina Clínica 2010;135:293-9. [DOI: 10.1016/j.medcli.2010.02.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
134 Denholm JT, McBryde ES. The use of anti-tuberculosis therapy for latent TB infection. Infect Drug Resist 2010;3:63-72. [PMID: 21694895 DOI: 10.2147/idr.s8994] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
135 Nuermberger EL, Spigelman MK, Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology 2010;15:764-78. [PMID: 20546189 DOI: 10.1111/j.1440-1843.2010.01775.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
136 Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010;375:2100-2109. [PMID: 20488518 DOI: 10.1016/s0140-6736(10)60359-9] [Cited by in Crossref: 256] [Cited by in F6Publishing: 273] [Article Influence: 19.7] [Reference Citation Analysis]
137 Minodier P, Lamarre V, Carle ME, Blais D, Ovetchkine P, Tapiero B. Evaluation of a school-based program for diagnosis and treatment of latent tuberculosis infection in immigrant children. J Infect Public Health 2010;3:67-75. [PMID: 20701894 DOI: 10.1016/j.jiph.2010.02.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
138 González-Martín J, García-García JM, Anibarro L, Vidal R, Esteban J, Blanquer R, Moreno S, Ruiz-Manzano J. [Consensus document on the diagnosis, treatment and prevention of tuberculosis]. Arch Bronconeumol 2010;46:255-74. [PMID: 20444533 DOI: 10.1016/j.arbres.2010.02.010] [Cited by in Crossref: 87] [Cited by in F6Publishing: 60] [Article Influence: 6.7] [Reference Citation Analysis]
139 González-martín J, García-garcía JM, Anibarro L, Vidal R, Esteban J, Blanquer R, Moreno S, Ruiz-manzano J. Consensus Document on the Diagnosis, Treatment and Prevention of Tuberculosis. Archivos de Bronconeumología ((English Edition)) 2010;46:255-74. [DOI: 10.1016/s1579-2129(10)70061-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
140 González-Martín J, García-García JM, Anibarro L, Vidal R, Esteban J, Blanquer R, Moreno S, Ruiz-Manzano J. [Consensus document on the diagnosis, treatment and prevention of tuberculosis]. Enferm Infecc Microbiol Clin 2010;28:297.e1-20. [PMID: 20435388 DOI: 10.1016/j.eimc.2010.02.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
141 Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update: Treatment of latent TB infection. Respirology 2010;15:603-22. [DOI: 10.1111/j.1440-1843.2010.01751.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 139] [Article Influence: 10.3] [Reference Citation Analysis]
142 Ma Z, Lienhardt C. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med 2009;30:755-68, ix. [PMID: 19925965 DOI: 10.1016/j.ccm.2009.08.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
143 Swaminathan S, Banu Rekha V. Drugs used in tuberculosis and leprosy. Side Effects of Drugs Annual 2010. [DOI: 10.1016/s0378-6080(10)32030-7] [Reference Citation Analysis]
144 Marais BJ, Ayles H, Graham SM, Godfrey-faussett P. Screening and Preventive Therapy for Tuberculosis. Clinics in Chest Medicine 2009;30:827-46. [DOI: 10.1016/j.ccm.2009.08.012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
145 Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review: Toxicity of first-line drugs for treatment of TB in children. Tropical Medicine & International Health 2009;14:1329-37. [DOI: 10.1111/j.1365-3156.2009.02375.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 3.6] [Reference Citation Analysis]
146 Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2009;180:1151-7. [PMID: 19729664 DOI: 10.1164/rccm.200905-0795OC] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 3.9] [Reference Citation Analysis]
147 Marais BJ, Schaaf HS, Donald PR. Pediatric TB: issues related to current and future treatment options. Future Microbiology 2009;4:661-75. [DOI: 10.2217/fmb.09.39] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
148 Malaviya AN, Kapoor S, Garg S, Rawat R, Shankar S, Nagpal S, Khanna D, Furst DE. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report. J Rheumatol 2009;36:1414-20. [PMID: 19487263 DOI: 10.3899/jrheum.081042] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
149 Spiegler P. Reviving Latent Research in Tuberculosis. Clinical Pulmonary Medicine 2009;16:108. [DOI: 10.1097/cpm.0b013e31819b3477] [Reference Citation Analysis]
150 Cruz AT, Starke JR. Treatment of tuberculosis in children. Expert Rev Anti Infect Ther 2008;6:939-57. [PMID: 19053906 DOI: 10.1586/14787210.6.6.939] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
151 Starke JR. TUBERCULOSIS. Feigin and Cherry's Textbook of Pediatric Infectious Diseases 2009. [DOI: 10.1016/b978-1-4160-4044-6.50112-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
152 Ruiz-manzano J, Blanquer R, Luis Calpe J, Caminero JA, Caylà J, Domínguez JA, María García J, Vidal R. Diagnóstico y tratamiento de la tuberculosis. Archivos de Bronconeumología 2008;44:551-66. [DOI: 10.1157/13126836] [Cited by in Crossref: 103] [Cited by in F6Publishing: 104] [Article Influence: 6.9] [Reference Citation Analysis]
153 Wu SS. Tuberculosis and hepatic toxicity in children. Pediatric Health 2008;2:463-475. [DOI: 10.2217/17455111.2.4.463] [Reference Citation Analysis]
154 Belley A, Neesham-Grenon E, Arhin FF, McKay GA, Parr TR Jr, Moeck G. Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:3820-2. [PMID: 18644953 DOI: 10.1128/AAC.00361-08] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
155 Powell DA, Perkins L, Wang SH, Hunt G, Ryan-Wenger N. Completion of therapy for latent tuberculosis in children of different nationalities. Pediatr Infect Dis J 2008;27:272-4. [PMID: 18277917 DOI: 10.1097/INF.0b013e3181609a0a] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
156 Magdorf K, Detjen AK. Proposed management of childhood tuberculosis in low-incidence countries. Eur J Pediatr 2008;167:927-38. [DOI: 10.1007/s00431-008-0730-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
157 Dufour V, Jouneau S, Pontier S. Tuberculose et collectivités d’enfants. Revue des Maladies Respiratoires 2008;25:117-119. [DOI: 10.1016/s0761-8425(08)56044-x] [Reference Citation Analysis]
158 Marguet C, Gut-robert C, André M. Particularités du traitement de la tuberculose chez l’enfant. Revue des Maladies Respiratoires 2008;25:67-8. [DOI: 10.1016/s0761-8425(08)56025-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
159 Marais BJ. Tuberculosis in children: Tuberculosis in Children. Pediatr Pulmonol 2008;43:322-9. [DOI: 10.1002/ppul.20787] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
160 Ruiz-manzano J, Blanquer R, Calpe JL, Caminero JA, Caylà J, Domínguez JA, María García J, Vidal R. Diagnosis and Treatment of Tuberculosis. Archivos de Bronconeumología ((English Edition)) 2008;44:551-66. [DOI: 10.1016/s1579-2129(08)60102-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
161 Shim TS, Koh W, Yim J, Lew WJ. Treatment of Latent Tuberculosis Infection in Korea. Tuberc Respir Dis 2008;65:79. [DOI: 10.4046/trd.2008.65.2.79] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]